SCHEMBL2851364

SCHEMBL2851364

CCC(CCC(C)=O)(C(=O)O)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
LMNA P02545 1/20 0.40
SLC15A2 Q16348 1/20 0.40
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
THRB P10828 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.35
FFAR3 O14843 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
ACHE P22303 1/20 0.30
PAOX Q6QHF9 1/20 0.30
KDM4E B2RXH2 1/20 0.30
KDM6B O15054 1/20 0.30
KDM5C P41229 1/20 0.30
EGLN1 Q9GZT9 1/20 0.30
PHF8 Q9UPP1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17767284 0.91 ALDH1A1 (0.38) ALDH1A1LMNASLC15A2MEN1CYP1A2
SCHEMBL17767286 0.91 ALDH1A1 (0.38) ALDH1A1LMNASLC15A2MEN1CYP1A2
SCHEMBL2844122 0.86 PTPN1 (0.34) ALDH1A1LMNASLC15A2MEN1CYP1A2
SCHEMBL17775403 0.83 ALDH1A1 (0.43) ALDH1A1LMNASLC15A2MEN1CYP1A2
SCHEMBL29271678 0.83 ALDH1A1 (0.43) ALDH1A1LMNASLC15A2MEN1CYP1A2
SCHEMBL11305844 0.83 ALDH1A1 (0.56) ALDH1A1LMNASLC15A2MEN1CYP1A2
SCHEMBL10844850 0.82 MEN1 (0.43) ALDH1A1LMNASLC15A2MEN1CYP1A2
SCHEMBL27614232 0.77 ALDH1A1 (0.50) ALDH1A1LMNASLC15A2MEN1CYP1A2
SCHEMBL1033008 0.77 ALDH1A1 (0.38) ALDH1A1LMNAMEN1CYP1A2THRB
SCHEMBL51201 0.76 FFAR3 (0.41) ALDH1A1MEN1CYP1A2THRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160670-A1 NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL-2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID AVENTIS PHARMA S.A. (FR) 2010-06-24 US disclosed
US-20090163737-A1 NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL 2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID AVENTIS PHARMA S.A. (FR) 2009-06-25 US disclosed
US-20080108847-A1 NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
EP-1578714-B1 NOVEL CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS, METHOD AND INTERMEDIATE CHEMICALS FOR THE PREPARATION AND USE THEREOF FOR SYNTHESIS OF 2-(BROMOMETHYL)2-ETHYL HEXANOIC CHIRAL ACID AVENTIS PHARMA SA (FR) 2007-08-08 EP disclosed
EP-1578714-A1 NOVEL CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS, METHOD AND INTERMEDIATE CHEMICALS FOR THE PREPARATION AND USE THEREOF FOR SYNTHESIS OF 2-(BROMOMETHYL)2-ETHYL HEXANOIC CHIRAL ACID Aventis Pharma S.A. (FR) 2005-09-28 EP disclosed
US-20040147774-A1 Novel chiral compounds derived from hexanoic acid esters, preparation process and intermediates, use in the synthesis of chiral 2-(bromomethyl)-2-ethylhexanoic acid AVENTIS PHARMA S.A. (FR) 2004-07-29 US disclosed
WO-2004058678-A1 NOVEL CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS, METHOD AND INTERMEDIATE CHEMICALS FOR THE PREPARATION AND USE THEREOF FOR SYNTHESIS OF 2-(BROMOMETHYL)2-ETHYL HEXANOIC CHIRAL ACID AVENTIS PHARMA S.A (FR) 2004-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108847-A1 NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID HCAR2, HCAR3, HCAR1 ALDH1A1 196/4885LMNA 3756/4885SLC15A2 3184/4885
US-20090163737-A1 NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL 2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID HCAR3, HCAR2, HCAR1 ALDH1A1 163/4885LMNA 3625/4885SLC15A2 3462/4885
US-20040147774-A1 Novel chiral compounds derived from hexanoic acid esters, preparation process and intermediates, use in the synthesis of chiral 2-(bromomethyl)-2-ethylhexanoic acid HCAR2, FFAR2, HCAR3 ALDH1A1 128/4885LMNA 3817/4885SLC15A2 3121/4885
US-20100160670-A1 NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL-2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID HCAR2, HCAR3, HCAR1 ALDH1A1 160/4885LMNA 3568/4885SLC15A2 3285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.